Anavex Life Sciences – pharmaceutical daily

May 22, 2017 Off

Anavex presents new data for certain neuro-diseases tratment

Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, has announced new preclinical data for ANAVEX 2-73 in the neurodevelopmental disorders Angelman syndrome, Fragile X syndrome and Rett syndrome.

May 10, 2017 Off

Anavex Life Sciences reports $1.5M net loss for Q1 2017

By Dino Mustafić

Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, todayhas reported financial results for the fiscal quarter ended March 31, 2017.

February 13, 2017 Off

Anavex appoints Peter Donhauser to its Board

By Dino Mustafić

Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, has appointed Peter Donhauser, D.O. to its Board of Directors.